AstraZeneca
This article was originally published in The Tan Sheet
Executive Summary
U.S. Patent & Trademark Office publishes 10 Prilosec OTC trademarks, with varying suffixes: OTC, Fast Action, AC, AP, Heartburn Preventer, Gelcap, Acid Inhibitor, Heartburn Blocker, PM and HB. AstraZeneca has a joint development and marketing deal with Procter & Gamble for an OTC version of omeprazole for heartburn (1"The Tan Sheet" Dec. 22, 1997, p. 2). Net sales of the Rx proton pump inhibitor in 1998 totaled $3.1 bil. A recent Campbell Mithun Esty Health study cited $50 mil. in DTC ad spending on Prilosec, which has been the subject of a new ad campaign (2"The Tan Sheet" July 19, p. 8)
You may also be interested in...
AstraZeneca Prilosec OTC Launch Anticipated For Second Quarter 2001
AstraZeneca's Prilosec proton pump inhibitor is anticipated to reach over-the-counter shelves in the second quarter of 2001.
Consumer Recall Of OTC Advertising "Much Higher" Than DTC Ads In Study
OTC advertising was found to generate "much higher awareness levels than their direct-to-consumer counterparts," Campbell Mithun Esty Health concludes in a two-part study conducted in November 1998 and last June. "Yet ad spending levels between the two groups were comparable," the firm notes, adding OTC brands spend an average $39.4 mil. in media, and DTC brands $43.6 mil.
Prilosec Rx-to-OTC switch for heartburn to be sought by P&G and Astra Merck.
PRILOSEC SWITCH TEAM P&G AND ASTRA MERCK will jointly contribute to the clinical work needed for approval of the Rx-to-OTC switch of the prescription ulcer drug omeprazole, and Procter & Gamble will handle the marketing of the OTC product once approved, the companies announced Dec. 15. Under the terms of the deal, P&G would make upfront payments to Astra Merck, plus royalties based on U.S. net sales of the OTC drug.